- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01700101
MelaFind Evaluations for Patients With Multiple Nevi
We have added objectives 4-6 to our updated study:
Study Objective 1: To determine whether the distribution of MelaFind scores is different for different patients with multiple nevi, and whether such distributions can be utilized to identify "signature" lesions for a given patient.
Study Objective 2: To investigate whether distributions of quantitative ABCD parameters differ among patients and whether these qABCD parameters identify "signature" lesions.
Study Objective 3: To determine the feasibility of defining and using relative thresholds to improve the specificity of MelaFind without sacrificing its high sensitivity.
Study Objective 4: To determine the repeatability of MelaFind scores for a given lesion for different patient and lesion characteristics.
Study Objective 5: To identify patient and lesion characteristics that result in the highest variability of MelaFind scores for a given lesion.
Study Objective 6: To use standard errors of MelaFind scores to propose a robust individual threshold for lesions to be considered for biopsy to rule out melanoma on patients with multiple nevi.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients who have at least one lesion that meets the inclusion/exclusion criteria (see eligibility criteria below) AND each lesion enrolled must be clinically atypical (i.e., contain at least one of the following ABCDEPRU characteristics: Asymmetry, Border irregularity, Color variegation, Diameter < 6 mm, Evolving, Patient's concern, Regression, Ugly duckling).
Lesions should be selected to have characteristics that may affect the repeatability of lesion scores: anatomic site (often exposed to UV - sun or tanning beds - or not; sun-damage may affect the repeatability); lesion diameter (6 mm, e.g. ~5 mm or > 6 mm, e.g., 10 mm); and melanin content relative to normal skin (dark pigmentation or light pigmentation).
A maximum of 8 lesions may be enrolled per patient
Description
Cutaneous lesions examined with MelaFind must satisfy all of the following inclusion criteria:
Inclusion Criteria:
- The lesion is pigmented (i.e., melanin, keratin, blood)
- The diameter of the pigmented area is not < 2 mm, and not > 22 mm
- The lesion is accessible to the MelaFind
- The patient, or a legally authorized representative, has consented to participate in the study and has signed the Informed Consent Form;
Cutaneous lesions that meet any of the following exclusion criteria will not be accepted:
Exclusion Criteria:
- The patient has a known allergy to isopropyl alcohol
- The lesion has been previously biopsied, excised, or traumatized
- The skin is not intact (e.g., open sores, ulcers, bleeding)
- The lesion is within 1 cm of the eye
- The lesion is on mucosal surfaces (e.g., lips, genitals)
- The lesion is on palmar hands
- The lesion is on plantar feet
- The lesion is on or under nails
- The lesion is located on or in an area of visible scarring
- The lesion contains foreign matter (e.g., tattoo, splinter, marker)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Multiple values and standard deviations of MelaFind scores for pigmented skin lesions
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20123
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinically Atypical Pigmented Skin Lesion
-
Massachusetts General HospitalEnrolling by invitationSkin Lesion | Pigmented Lesions | Pigmented Skin Lesion | Pigmented MolesUnited States
-
Candela CorporationMiami Dermatology and Laser InstituteCompletedPigmented Skin LesionUnited States
-
R2 DermatologyCompleted
-
Lumenis Be Ltd.Emek Medical CenterRecruitingPigmented Lesions | Vascular LesionIsrael
-
Lumenis Be Ltd.Emek Medical CenterRecruitingPigmented Lesions | Vascular LesionIsrael
-
Lumenis Be Ltd.CompletedPigmented Lesions | Vascular LesionUnited States
-
AVAVA, Inc.Completed
-
University of California, IrvineRecruitingPigmented Skin Lesion of Uncertain NatureUnited States
-
Cutera Inc.CompletedPigmented Skin Lesion of Suspected Benign NatureUnited States
-
AI Labs Group S.LInstituto de Dermatología Integral (IDEI)RecruitingAcne Vulgaris | Acne | Alopecia, Androgenetic | Pigmented Lesions | Pigmented Skin LesionSpain